Breast Cancer Growth Slowed by 14 Months in New AstraZeneca Drug Study 

AstraZeneca Plc and Daiichi Sankyo Co.’s Enhertu delayed the advance of a common type of breast cancer by more than a year in a large study, a result that may lead to expanded use of the medicine.

The treatment, already approved for several types of breast cancer, garnered sales of about $3.8 billion last year. It is routinely used as a second choice in roughly 20% of patients whose tumors have high levels of a protein called HER2.